Rationale and Design of the Persian CardioVascular Disease Registry (PCVDR): Scale-Up of Persian Registry Of CardioVascular DiseasE (PROVE)

• Published in: Current problems in cardiology 2021-03, Vol.46 (3), p.100577-100577, Article 100577
• Main Authors: Khosravi, Alireza, Mansouri, Asieh, Shahsanayi, Farzad, Paydari, Navid, Heshmat-Ghahdarijani, Kiyan, Mansourian, Marjan, Nouri, Fatemeh, Taheri, Marzieh, Farshidi, Hossein, Kazemi, Toba, Khaledifar, Arsalan, Assareh, Ahmadreza, Behnammoghadam, Mohammad, Peighambari, Mohammad Mehdi, Nematipour, Ebrahim, Nizal Sarrafzadegan, Feridoun Noohi
• Format: Article
• Language: English
• ISSN: 0146-2806; 1535-6280
• DOI: 10.1016/j.cpcardiol.2020.100577

We aimed to present the methodology of a national registry entitled “Persian CardioVascular Disease Registry (PCVDR).” Persian Registry Of cardioVascular diseasE (PROVE) was a demonstration registry conducted in Isfahan since 2014 to test the feasibility and practicality of PCVDR in Iran. Built on that experience, the first phase of PCVDR that consist of angiography and percutaneous coronary intervention (PCI) registry at national level started in March 2017. Currently, PCVDR is in place in 19 hospitals, located in 7 provinces. Five questionnaires including basic information, angiography, and PCI techniques, discharge and follow-up were completed for registered patients. Since beginning until October 7th, 2019, the number of angiography and PCI cases registered in all provinces were 37,120 and 16,277, respectively. Of all PCI cases registered, 11,846 patients (72.8%) were followed up until 12 months. We expect that this registry be expanded to cover most hospitals and centers with cardiology departments in the country.